Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on January 31, 2022. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California. The filing discloses a material financial event involving the final drawdown of a secured convertible credit facility.
Key Financial Metrics and Obligations
- Debt Financing: AgeX borrowed an additional $0.5 million on January 31, 2022, under a Secured Convertible Facility Agreement with Juvenescence Limited.
- Facility Status: This drawdown represents the final available credit under the 2020 Loan Agreement; the full credit amount has now been utilized.
- Repayment Terms: The outstanding principal balance is due and payable on March 30, 2023.
- Equity Issuance: In connection with the loan, AgeX will issue unregistered warrants to purchase 308,565 shares of common stock at an exercise price of $0.8102 per share.
- Liquidity and Cash Flow: The filing does not provide specific cash flow statements, revenue figures, or current liquidity ratios.
Material Changes and Events
The primary material change is the execution of the final loan tranche, which increases the company's total debt obligation under the 2020 Loan Agreement to its maximum capacity. Concurrently, the company has created a new obligation to issue equity warrants, which may result in future dilution if exercised. No revenue or profit changes are reported in this specific filing.
Guidance, Risks, and Contingencies
- Events of Default: The loan agreement contains extensive default provisions. Juvenescence may declare the debt immediately due if AgeX fails to pay within 10 business days, becomes insolvent, or if other indebtedness exceeding $100,000 becomes due. Other triggers include the loss of material collateral or a material adverse change in financial condition.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors detailed in periodic reports.
- Unregistered Securities: The warrants are issued in reliance on Section 4(a)(2) and Regulation S exemptions, meaning they are not registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the total outstanding principal balance of the 2020 Loan Agreement after the $0.5 million drawdown.
- Confirm the listing approval status of the 308,565 warrants on the NYSE American.
- Review the company's current cash position to assess ability to meet the March 30, 2023, repayment date.
- Check for any existing "Events of Default" or cross-default triggers related to other indebtedness exceeding $100,000.
- Examine the full text of the Warrant Agreement and Security Agreement filed as exhibits to the 2020 10-K and 2020 10-Q for specific covenants.